653P - Differences in gastric adenocarcinoma patients at extremes of the age spectrum

Date 08 October 2016
Event ESMO 2016 Congress
Session Poster Display
Topics Gastric Cancer
Presenter Ryan Rhome
Citation Annals of Oncology (2016) 27 (6): 207-242. 10.1093/annonc/mdw371
Authors R. Rhome1, U. Ozbek2, R.F. Holcombe3, M. Buckstein4, C. Ang5
  • 1Radiation Oncology, Tisch Cancer Institute, Mount Sinai School of Medicine, 10029 - New York/US
  • 2Biostatistics, Tisch Cancer Institute, Mount Sinai School of Medicine, New York/US
  • 3Medicine, Tisch Cancer Institute, Mount Sinai School of Medicine, New York/US
  • 4Radiation Oncology, Tisch Cancer Institute, Mount Sinai School of Medicine, New York/US
  • 5Medicine, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, 10029 - New York/US



Patients (pts) at the extremes of the age spectrum are often under-represented in gastric cancer trials (median age of inclusion was 56-62 years old (y/o) in major studies). Large population-based databases are useful to characterize the demographics, treatment patterns, and outcomes of these pts.


We obtained de-identified demographic, staging, and treatment information on gastric adenocarcinoma (GA) pts 18-90 y/o diagnosed between 2004-2013 from the National Cancer Database. The cohort was divided into young adults (YAs, 18-39 y/o), extreme elderly pts (EE, 75-90 y/o) and remaining pts into a middle age group (MA, 40-74 y/o). Differences amongst the groups were evaluated and compared using Pearson's chi-squared test.


The total cohort included 118,417 pts: YAs (n = 3,997, 3.4%), MA (n = 77,292 65.3%), and EE (n= 37,128, 31.3%). Results are summarized as percentages in the table to reflect effect size given the large cohort. All differences amongst the groups were statistically significant (p  75 years old, a higher proportion of whom are not treated.

Sex (N = 118,417) Male/Female 52.8%/47.2% 66.6%/33.4% 58.1%/41.9%
Race (N = 115,372) White/Black/Asian 72.0%/ 18.5%/ 9.5% 76.6%/ 16.6%/ 6.8% 80.9%/ 12.9%/ 6.1%
Ethnicity (N = 111,467) Hispanic/non-Hispanic 29.6%/70.3% 11.3%/88.7% 7.2%/92.8%
Stage (N = 118,417) I/II/III/IV 16.0%/10.5%/18.4%/55.2% 22.9%/15.2%/21.1%/40.9% 30.5%/16.0%/18.4%/35.1%
Grade (N = 94,326) 1/2/3 6.2%/13.9%/79.9% 7.6%/26.9%/65.5% 7.5%/32.4%/60.1%
Subtype (N = 11,110) Intestinal/diffuse 30.3%/69.7% 66.7%/33.3% 80.1%/19.9%
Treatment (N = 82,765) Surgery Surgery + chemo Surgery + chemoRT None 25.7% 23.6% 28.8% 21.8% 34.6% 17.3% 27.6% 20.4% 47.9% 7.2% 8.7% 36.2%


Differences exist between age extremes in GA patients compared to those traditionally represented in landmark trials including demographics, stage of presentation, histologic subtype, and treatment utilization. Further investigation is warranted to determine the effects of these differences on outcome.

Clinical trial identification

Legal entity responsible for the study

This study is a retrospective review. No legal entities were involved in the conduct of this study.


Mount Sinai School of Medicine


All authors have declared no conflicts of interest.